|
Research
Front Name
|
Percentage of corporate affiliations
|
Leading
corporation
|
|
METABOLITE IDENTIFICATION; EARLY DRUG DISCOVERY USING
HIGH-RESOLUTION LIQUID CHROMATOGRAPHY/QUADRUPOLE
TIME-OF-FLIGHT MASS SPECTROMETRY
|
40
|
Waters Corp
|
|
FULLY HUMAN TRAIL-RECEPTOR 1 MONOCLONAL ANTIBODY; TUMOR
NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND
RECEPTOR-1; CELL DEATH
|
39
|
Genentech, Inc
|
|
HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS; HEPATITIS
C VIRUS NS3-4A SERINE PROTEASE; RESISTANT GENOTYPE 1
HEPATITIS C VIRUS REPLICATION
|
27
|
Vertex Pharmaceuticals, Inc
|
|
THERAPEUTIC RNAI TARGETING PCSK9; PLASMA CHOLESTEROL;
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9
NEUTRALIZING ANTIBODY REDUCES SERUM CHOLESTEROL
|
27
|
Alnylam Pharmaceuticals, Inc
|
|
TYPE 2 DIABETES MELLITUS; TYPE 2 DIABETES FAILING
THIAZOLIDINEDIONE MONOTHERAPY; SUBOPTIMALLY CONTROLLED
TYPE 2 DIABETES
|
25
|
Merck & Co, Inc
|
|
ACUTE CORONARY SYNDROME; CORONARY STENTING; PROTON PUMP
INHIBITORS FOLLOWING ACUTE CORONARY SYNDROME; STENT
THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
|
24
|
Eli Lilly & Co
|
|
MOLECULAR DOCKING ACCURACY; VIRTUAL SCREENING USING
PROTEIN-LIGAND DOCKING; MOLECULAR DOCKING USING
POLYNOMIAL EMPIRICAL SCORING FUNCTIONS
|
24
|
Schrodinger, LLC
|
|
DELTA-LIKE 4 NOTCH LIGAND; TUMOR ANGIOGENESIS; BLOCKING
NEUROPILIN-2 FUNCTION INHIBITS TUMOR CELL METASTASIS;
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
|
21
|
Regeneron Pharmaceuticals, Inc
|
|
NONINFLAMMATORY SYNTHETIC SIRNA; POTENT GENE SILENCING
IN-VIVO; SYSTEMIC LEUKOCYTE-DIRECTED SIRNA DELIVERY;
POLYETHYLENIMINE (PEI)-COMPLEXED SIRNA IN-VIVO
View Research Front Map for this
front:
"GENE SILENCING USING SMALL
INTERFERING RNAS"
|
20
|
Alnylam Pharmaceuticals, Inc
|
